Nicola J Graham

Learn More
PURPOSE To conduct a phase I clinical trial with a second-generation oncolytic herpes simplex virus (HSV) expressing granulocyte macrophage colony-stimulating factor (Onco VEXGM-CSF) to determine the safety profile of the virus, look for evidence of biological activity, and identify a dosing schedule for later studies. EXPERIMENTAL DESIGN The virus was(More)
9521 Background: This phase I study evaluated the tolerability of clofarabine with liposomal daunorubicin in childhood refractory/relapsed AML. Clofarabine is a purine nucleoside analogue, approved by EMA and FDA in relapsed/refractory childhood ALL but its application in childhood AML is unproven. AML17, the UK front line study for AML is investigating the(More)
  • 1